GVK Bio has announced the signing of a definitive agreement to acquire Vanta Bioscience.
Commenting on the acquisition, Manni Kantipudi, CEO, GVK BIO, said: “The acquisition is in line with our business strategy of being an integrated drug discovery services provider for our customers. We are constantly investing in upgrading our capabilities to provide world-class R&D services. Vanta Bioscience further advances our position as we expand our service offering in GLP toxicology.”
The Hyderabad-based company did not disclose the financials of the acquisition. Vanta Bioscience is a contract research organisation. The company offers toxicology evaluation services for the pharmaceutical, biotech, food supplements and feed additives industries. Vanta Bioscience also offers toxicology services using alternative methods for the cosmetics industry.
Gerard Schwickerath, Vice-President and General Manager, Vanta Bioscience said: The company will continue doing its core activity under the direction of GVK BIO and provide further opportunities to our clients and staff. Business Line
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…